CD47 and neoplasm: Our data showed a strong additive effect of doxorubicin plus CD47 mAb combination therapy in mouse models of osteosarcomas, which led to significantly inhibited tumor growth and significantly improved survival of tumor‐bearing mice compared to CD47 mAb alone and doxorubicin alone.